利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.04 秒)

    IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS
    1.
    发明申请
    IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS 有权
    具有外膜蛋白的免疫细菌性细菌

    公开(公告)号：US20100015212A1

    公开(公告)日：2010-01-21

    申请号：US11666786

    申请日：2005-10-28

    申请人： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

    发明人： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

    IPC分类号： A61K9/127 ,  C12N1/20 ,  C12N1/00 ,  A61K35/04

    CPC分类号： C07K14/245 ,  A61K39/00 ,  A61K39/0258 ,  A61K39/095 ,  C07K14/22 ,  C12N9/1051 ,  Y02A50/474

    摘要： Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity of MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.

    摘要翻译： 脑膜炎球菌mltA同系物的敲除使细菌自发释放富含免疫原性外膜蛋白的囊泡，并且能够以比正常生产过程制备的OMV更高的杀菌滴度引发交叉保护性抗体应答。 因此，本发明提供了具有其mltA基因的敲除突变的细菌。 本发明还提供了一种细菌，其中所述细菌：（i）具有包含肽聚糖的细胞壁; 和（ii）不表达具有MltA蛋白的裂解转糖苷酶活性的蛋白质。 本发明还提供包含囊泡的组合物，其在本发明的细菌培养期间释放到培养基中。

    Immunogenic bacterial vesicles with outer membrane proteins
    2.
    发明授权
    Immunogenic bacterial vesicles with outer membrane proteins 有权
    具有外膜蛋白的免疫原性细胞囊泡

    公开(公告)号：US09206399B2

    公开(公告)日：2015-12-08

    申请号：US11666786

    申请日：2005-10-28

    申请人： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

    发明人： Jeannette Adu-Bobie ,  Mariagrazia Pizza ,  Nathalie Norais ,  Germano Ferrari ,  Guido Grandi

    IPC分类号： A61K39/095 ,  C12N9/10 ,  A61K39/108

    CPC分类号： C07K14/245 ,  A61K39/00 ,  A61K39/0258 ,  A61K39/095 ,  C07K14/22 ,  C12N9/1051 ,  Y02A50/474

    摘要： Knockout of the meningococcal mltA homolog gives bacteria that spontaneously release vesicles that are rich in immunogenic outer membrane proteins and that can elicit cross-protective antibody responses with higher bactericidal titres than OMVs prepared by normal production processes. Thus the invention provides a bacterium having a knockout mutation of its mltA gene. The invention also provides a bacterium, wherein the bacterium: (i) has a cell wall that includes peptidoglycan; and (ii) does not express a protein having the lytic transglycosylase activity of MltA protein. The invention also provides compositions comprising vesicles that, during culture of bacteria of the invention, are released into the culture medium.

    摘要翻译： 脑膜炎球菌mltA同系物的敲除使细菌自发释放富含免疫原性外膜蛋白的囊泡，并且能够以比正常生产过程制备的OMV更高的杀菌滴度引发交叉保护性抗体应答。 因此，本发明提供了具有其mltA基因的敲除突变的细菌。 本发明还提供了一种细菌，其中所述细菌：（i）具有包含肽聚糖的细胞壁; 和（ii）不表达具有MltA蛋白的裂解转糖苷酶活性的蛋白质。 本发明还提供包含囊泡的组合物，其在本发明的细菌培养期间释放到培养基中。

    IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS AGALACTIAE
    8.
    发明申请
    IMMUNOGENIC COMPOSITIONS FOR STREPTOCOCCUS AGALACTIAE 审中-公开
    用于结核分枝杆菌的免疫组化

    公开(公告)号：US20100015168A1

    公开(公告)日：2010-01-21

    申请号：US12303999

    申请日：2007-06-11

    申请人： Domenico Maione ,  Guido Grandi ,  Nathalie Norais

    发明人： Domenico Maione ,  Guido Grandi ,  Nathalie Norais

    IPC分类号： A61K39/00 ,  G01N33/53 ,  C12N15/63 ,  C07K14/00 ,  C07H21/04

    CPC分类号： A61K39/092 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/315 ,  G01N33/56944 ,  G01N2469/20

    摘要： The invention relates to immunogenic polypeptides derived from epitopes in a Streptococcus agalactiae (“GBS”) protein GBS 80 and their use as prophylactic, diagnostic and therapeutic compositions. The invention also provides nucleic acids encoding the immunogenic polypeptides. Also provided are vectors useful for making such immunogenic polypeptides and host cells transformed with such vectors. In particular, the invention relates to a group immunogenic polypeptides derived from GBS 80. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other GBS antigens to provide therapeutic compositions with broader range. In addition, the immunogenic polypeptides may also include flanking portions of the GBS 80 protein.

    摘要翻译： 本发明涉及源自无乳链球菌（GBS）蛋白GBS 80中的表位的免疫原性多肽及其作为预防，诊断和治疗组合物的用途。 本发明还提供编码免疫原性多肽的核酸。 还提供了可用于制备这种免疫原性多肽的载体和用这些载体转化的宿主细胞。 特别地，本发明涉及衍生自GBS80的组免疫原性多肽。组合物可以单独或与其它抗原成分一起包括一种或多种免疫原性多肽。 例如，免疫原性多肽可以与其他GBS抗原组合以提供更宽范围的治疗组合物。 此外，免疫原性多肽还可以包括GBS 80蛋白的侧翼部分。

    Immunogenic Compositions for Streptococcus agalactiae
    9.
    发明申请
    Immunogenic Compositions for Streptococcus agalactiae 审中-公开
    无乳链球菌的免疫原性组合物

    公开(公告)号：US20120141521A1

    公开(公告)日：2012-06-07

    申请号：US13339628

    申请日：2011-12-29

    申请人： Domenico Maione ,  Guido Grandi ,  Nathalie Norais

    发明人： Domenico Maione ,  Guido Grandi ,  Nathalie Norais

    IPC分类号： A61K39/09 ,  A61P37/04 ,  A61P31/04 ,  C07K14/315

    CPC分类号： A61K39/092 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/315 ,  G01N33/56944 ,  G01N2469/20

    摘要： The invention relates to immunogenic polypeptides derived from epitopes in a Streptococcus agalactiae (“GBS”) protein GBS 80 and their use as prophylactic, diagnostic and therapeutic compositions. The invention also provides nucleic acids encoding the immunogenic polypeptides. Also provided are vectors useful for making such immunogenic polypeptides and host cells transformed with such vectors. In particular, the invention relates to a group immunogenic polypeptides derived from GBS 80. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other GBS antigens to provide therapeutic compositions with broader range. In addition, the immunogenic polypeptides may also include flanking portions of the GBS 80 protein

    摘要翻译： 本发明涉及源自无乳链球菌（GBS）蛋白GBS 80中的表位的免疫原性多肽及其作为预防，诊断和治疗组合物的用途。 本发明还提供编码免疫原性多肽的核酸。 还提供了可用于制备这种免疫原性多肽的载体和用这些载体转化的宿主细胞。 特别地，本发明涉及衍生自GBS80的组免疫原性多肽。组合物可以单独或与其它抗原成分一起包括一种或多种免疫原性多肽。 例如，免疫原性多肽可以与其他GBS抗原组合以提供更宽范围的治疗组合物。 此外，免疫原性多肽还可以包括GBS 80蛋白的侧翼部分

    Unexpected surface proteins in meningococcus
    10.
    发明申请
    Unexpected surface proteins in meningococcus 审中-公开
    脑膜炎球菌中意外的表面蛋白

    公开(公告)号：US20070059329A1

    公开(公告)日：2007-03-15

    申请号：US10535168

    申请日：2003-11-17

    申请人： Nathalie Norais ,  Guido Grandi

    发明人： Nathalie Norais ,  Guido Grandi

    IPC分类号： A61K39/095 ,  C07K14/22

    CPC分类号： C07K14/22

    摘要： 217 proteins have, contrary to expectations, been found in the membrane of Neisseria meningitidis. Of these 217, 76 in particular evaded all algorithmic methods for predicting membrane localisation. Existing knowledge of protein trafficking pathways in meningococcus does not explain how or why these proteins are located in the bacterial membrane e.g. there is no apparent biochemical reason for a DNA helicase or a chromosomal replication initiator protein to be found in the membrane. These 217 proteins are provided as membrane proteins.

    摘要翻译： 与脑膜炎奈瑟氏球菌膜中发现的217个蛋白质有相反的期望。 在这217个中，76个特别回避了用于预测膜定位的所有算法方法。 脑膜炎球菌中蛋白质运输途径的现有知识并不解释这些蛋白质如何位于细菌膜中，如何。 在膜中没有发现DNA解旋酶或染色体复制引发蛋白的明显的生物化学原因。 这些217蛋白质作为膜蛋白提供。